Empasiprubart IV Clinical Trials (2026): 8 Studies for AChR-Ab Seropositive Generalized Myasthenia Gravis & Chronic Inflammatory Demyelinating Polyneuropathy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
8 Empasiprubart IV clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including AChR-Ab Seropositive Generalized Myasthenia Gravis & Chronic Inflammatory Demyelinating Polyneuropathy) and 865 total planned enrollment. 3 Phase 3 Empasiprubart IV trials and 2 Phase 2 are listed. 6 Empasiprubart IV clinical trials are actively recruiting at 37 U.S. sites across 12 states. Most recent activity: NCT07091630 (Jan 2031).
Where to Participate: All Empasiprubart IV Trial Sites in the U.S. (37 sites across 12 states)
Every actively recruiting Empasiprubart IVtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Profound Research LLC - Carlsbad | Carlsbad92011 | NCT07284420 | Map |
| CA | Profound Research LLC - Carlsbad | Carlsbad92011 | NCT07294170 | Map |
| CA | Samir Macwan, M.D., Inc. | Rancho Mirage922701 | NCT06920004 | Map |
| CA | Samir Macwan, M.D., Inc. (S corporation) | Rancho Mirage92270 | NCT07091630 | Map |
| CO | Colorado Springs Neurological Associates | Colorado Springs80907 | NCT06920004 | Map |
| CO | Colorado Springs Neurological Associates | Colorado Springs80907 | NCT07091630 | Map |
| DC | Medstar Health Research Institute | Washington D.C.20010 | NCT07091630 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT06920004 | Map |
| FL | Homestead Associates in Research Inc | Homestead33033 | NCT06920004 | Map |
| FL | Gables Neurology | Miami33133 | NCT07091630 | Map |
| FL | Visionary Investigators Network | Miami33176 | NCT07284420 | Map |
| FL | Visionary Investigators Network | Miami33133 | NCT07294170 | Map |
| FL | Visionary Investigators Network | Miami33133 | NCT06920004 | Map |
| FL | Aqualane Clinical Research | Naples34105 | NCT07091630 | Map |
| FL | University of South Florida | Tampa33620 | NCT07284420 | Map |
| FL | University of South Florida | Tampa33620 | NCT07294170 | Map |
| FL | University of South Florida | Tampa33616 | NCT06920004 | Map |
| LA | Paradigm Health System | Slidell70458 | NCT06920004 | Map |
| LA | Paradigm Health System | Slidell70458 | NCT07091630 | Map |
| MD | Erlanger Health System | Columbia21044 | NCT07294170 | Map |
| MD | Erlanger Health System | Columbia21044 | NCT06920004 | Map |
| MI | University of Michigan Hospital | Ann Arbor48109 | NCT06920004 | Map |
| NY | Dent Neurologic Institute - Amherst | Amherst14226 | NCT07284420 | Map |
| NY | Dent Neurologic Institute - Amherst | Amherst14226 | NCT07294170 | Map |
| OH | Ohio State Martha Morehouse Outpatient Care | Columbus43221-3502 | NCT07284420 | Map |
| OH | Ohio State Martha Morehouse Outpatient Care | Columbus43221-3502 | NCT07294170 | Map |
| PA | Penn Medicine University City | Philadelphia19104-5545 | NCT07091630 | Map |
| TN | Erlanger Health System | Chattanooga37403 | NCT07284420 | Map |
| TN | Erlanger Health System | Chattanooga37403-2136 | NCT07294170 | Map |
| TX | National Neuromuscular Research Institute | Austin78756 | NCT07284420 | Map |
| TX | National Neuromuscular Research Institute | Austin78759 | NCT07294170 | Map |
| TX | National Neuromuscular Research Institute | Austin78756 | NCT07091630 | Map |
| TX | NeuroCarePlus | Houston77094 | NCT06920004 | Map |
| TX | NeuroCarePlus | Houston77094 | NCT07091630 | Map |
| TX | National Neuromuscular Research Institute | Irving75063 | NCT06920004 | Map |
| TX | University of Texas- San Antonio - Health Science Center - PPDS | San Antonio78229 | NCT07284420 | Map |
| TX | University of Texas- San Antonio - Health Science Center - PPDS | San Antonio78229 | NCT07294170 | Map |
Empasiprubart IV clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | 2 | |
| P2 | 1 | 1 | 2 | |
| P3 | 2 | 1 | 3 | |
| N/A | 1 | 1 |
Recruiting Empasiprubart IV clinical trials (6)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07091630 | emnergizeA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | P3 | Chronic Inflammatory Demyelinating Polyneuropathy | 160 | Sep 2025 |
| NCT06920004 | emvigorateA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | P3 | Chronic Inflammatory Demyelinating Polyneuropathy | 218 | Aug 2025 |
| NCT07610564 | EmpaSoundA Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy | P1 | Multifocal Motor Neuropathy (MMN) | 60 | Jun 2026 |
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | P2 | AChR-Ab Seropositive Generalized Myasthenia Gravis | 70 | Dec 2025 |
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | — | Myasthenia Gravis | 70 | Dec 2025 |
| NCT07612020 | IVA Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants | P1 | Healthy Volunteers | 130 | Mar 2026 |
Empasiprubart IV clinical trials by indication
Multifocal Motor Neuropathy (MMN) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07610564 | EmpaSound | P1 | not yet recruiting | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy |
| NCT06742190 | Empassion | P3 | active not recruiting | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy |
Chronic Inflammatory Demyelinating Polyneuropathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07091630 | emnergize | P3 | recruiting | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP |
| NCT06920004 | emvigorate | P3 | recruiting | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07612020 | IV | P1 | recruiting | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants |
AChR-Ab Seropositive Generalized Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07284420 | — | P2 | recruiting | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod |
Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07294170 | — | N/A | recruiting | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis |
Dermatomyositis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06284954 | empacific | P2 | active not recruiting | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis |
Empasiprubart IV pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| emnergize | NCT07091630 | P3 | recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 160 | — |
| emvigorate | NCT06920004 | P3 | recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 218 | — |
| Empassion | NCT06742190 | P3 | active not recruiting | Multifocal Motor Neuropathy (MMN) | 154 | PMID 40913126 |
| empacific | NCT06284954 | P2 | active not recruiting | Dermatomyositis | 3 | — |
All Empasiprubart IV trials (8)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07091630 | emnergize | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | P3 | recruiting | 160 | argenx | Sep 2025 |
| NCT06920004 | emvigorate | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | P3 | recruiting | 218 | argenx | Aug 2025 |
| NCT07610564 | EmpaSound | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy | P1 | not yet recruiting | 60 | argenx | Jun 2026 |
| NCT06742190 | Empassion | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | P3 | active not recruiting | 154 | argenx | Dec 2024 |
| NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | P2 | recruiting | 70 | argenx | Dec 2025 | |
| NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | — | recruiting | 70 | argenx | Dec 2025 | |
| NCT07612020 | IV | A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants | P1 | recruiting | 130 | argenx | Mar 2026 |
| NCT06284954 | empacific | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | P2 | active not recruiting | 3 | argenx | Aug 2024 |
Empasiprubart IV clinical trials: frequently asked questions
- How many Empasiprubart IV clinical trials are there?
- 8 Empasiprubart IV clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants.
- Are Empasiprubart IV clinical trials recruiting in 2026?
- Yes — 5 Empasiprubart IV trials are actively recruiting in 2026, with 37 U.S. sites across 12 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Empasiprubart IV being studied for?
- Empasiprubart IV is being studied for AChR-Ab Seropositive Generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), gMG and 10 more. The trials are grouped by indication on this page.
- What phase is Empasiprubart IV in?
- Empasiprubart IV clinical trials span 3 Phase 3, 2 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Empasiprubart IV clinical trials?
- The lead sponsor across the most Empasiprubart IV trials is argenx. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Empasiprubart IVas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: